Oxford Biodynamics Plc (LON:OBD) Director of Business Development & Head of Statistics Dr. Ewan Hunter talks to DirectorsTalk about the publication of a paper in the Journal of Translational Medicine. Ewan provides a summary of the paper, explains the impact towards precision medicine, how this work fits into the landscape of chromosome architecture, regulation of gene expression and the control of the genome via the non-coding genome. Ewan also explains how OBD is extending this work.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.